CyPass Recall from an Expert’s Perspective

In this EyeNet interview from AGS 2019, Dr. Thomas Samuelson offers his opinion on Alcon’s decision to withdraw the CyPass microstent from global markets. In his opinion, the device may still represent an ideal option for those with severe refractory glaucoma. However, patients with subclinical or preperimetric glaucoma should be protected from potential endothelial cell loss. Dr. Samuelson hopes that CyPass’ recall will not deter new inventions in the field of surgical glaucoma.

Learn more about this topic in this article from the February 2019 issue of EyeNet.

Relevant Financial Disclosures: Dr. Samuelson is a consultant for Alcon